TABLE 1.
Patient characteristics at baseline
| RYGB (n = 40) | Diet (n = 41) | Control (n = 18) | |
|---|---|---|---|
| Age (years) | 46 ± 9.0 | 49 ± 10 | 42 ± 15 |
| Sex (female/male) | 27/13 | 27/14 | 15/3 |
| Ethnicity (Caucasian/other) | 40/0 | 40/1 | 17/1 |
| Body weight (kg) | 132 ± 24 | 124 ± 23 | 71 ± 11 |
| BMI (kg/m2) | 45 ± 6 | 42 ± 5 | 25 ± 3 |
| NAFLD liver fat score | 2.7 ± 2.8 | 2.1 ± 2.8 | −1.7 ± 1.0 |
| Liver fat content (%) | 11 ± 6.2 | 10 ± 7.2 | 2.5 ± 1.3 |
| ALAT (U/L) | 34 ± 17 | 32 ± 18 | 22 ± 15 |
| Creatinine (μmol/L) | 58 ± 11 | 59 ± 14 | 60 ± 12 |
| Albumin (g/L) | 40 ± 2.2 | 40 ± 2.1 | 40 ± 2.4 |
| Hs‐CRP (mg/L) | 8.2 ± 6.2 | 8.2 ± 9.5 | 2.5 ± 3.8 |
| CYP1A2 genotype (likely phenotype) | |||
| *1/*1 or *1/*1F (NM) | 19 (48%) | 19 (46%) | 11 (61%) |
| *1F/*1F (hyperinducer) | 21 (53%) | 22 (54%) | 7 (39%) |
| CYP2C19 genotype (likely phenotype) | |||
| *1/*1 (NM) | 12 (30%) | 20 (49%) | 8 (44%) |
| *17/*17 or *1/*17 (UM/RM) | 15 (38%) | 15 (37%) | 5 (28%) |
| *1/*2 or *2/*17 (IM) | 10 (25%) | 5 (12%) | 5 (28%) |
| *2/*2 or *2/*4 (PM) | 3 (7.5%) | 1 (2.4%) | 0 (0.0%) |
| CYP2C9 genotype (likely phenotype) | |||
| *1/*1 or *1/*2 (NM) | 36 (90%) | 38 (93%) | 17 (94%) |
| *1/*3 or *2/*2 (IM) | 4 (10%) | 3 (7.3%) | 0 (0.0%) |
| *3/*3 (PM) | 0 (0.0%) | 0 (0.0%) | 1 (5.6%) |
Note: Data are presented as mean ± SD or number (%). Patient characteristics at baseline are given for patients supplying at least one metabolic ratio during the study period.
Abbreviations: ALAT, alanine aminotransferase; BMI, body mass index; CYP, cytochrome P450; hs‐CRP, high‐sensitivity C‐reactive protein; IM, intermediate metabolizer; NAFLD, nonalcoholic fatty liver disease; NM, normal metabolizer; PM, poor metabolizer; RM, rapid metabolizer; RYGB, Roux‐en‐Y gastric bypass; UM, ultrarapid metabolizer.